Is BCI funding ahead of the medicine?
A $9B valuation for Neuralink prices in a future where brain implants are routine — but today's devices help a few dozen people in trials. Our read on the gap between capital and clinical reality. (Our opinion, not investment advice.)
Neuralink's reported $9B valuation, and the hundreds of millions flowing to Synchron, Paradromics and Precision, price in a world where brain implants are a routine medical product. Today's reality is earlier than that: a few dozen people across all companies are living with these devices, almost entirely within investigational trials, and not one has an FDA approval for routine commercial use.
Our read is that capital is ahead of the medicine — which is not the same as saying it is wrong. Unlike a consumer gadget, a BCI advances at the pace of surgery, regulation and multi-year safety data, and those clocks do not speed up with funding. The upside is genuinely large if implants restore communication or movement at scale; the risk is that timelines are biological and regulatory, not financial, so the wait between a striking demo and an approved therapy can be long.
We think the sober way to read this field is to weigh the valuations against the boring metrics — humans implanted, electrodes that actually work in people, and regulatory clearances — rather than the demo of the week. Precision's FDA clearance and Synchron's ten patients are, to us, worth more than any headline number.
This is our interpretation of the public data, not investment advice.